Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 9Recruiting 9Not yet recruiting 6Terminated 3Completed 3Active not recruiting 3Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 472Prostatic Neoplasms 420Neoplasms 379Multiple Myeloma 261Colorectal Neoplasms 261Lung Neoplasms 248Neoplasm Metastasis 230Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 190Pancreatic Neoplasms 181Squamous Cell Carcinoma of Head and Neck 163Recurrence 146Carcinoma, Renal Cell 144Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 134Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Hepatocellular 123Brain Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

trastuzumab deruxtecan 1sintilimab 1pembrolizumab 1durvalumab 1cabozantinib 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Gastric Adenocarcinoma × Clear all
NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

National Cancer Center Hospital East

Phase 2 Active not recruiting
64 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 2 Active not recruiting
34 enrolled 11 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡